|
Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Speakers' Bureau - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Research Funding - Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
|
No Relationships to Disclose |